Spinocerebellar ataxia 7
MONDO:0016163Also known as: ADCA2, ADCAII, ATXN7 autosomal dominant cerebellar ataxia type II, SCA7, ataxia with pigmentary retinopathy, autosomal dominant cerebellar ataxia type 2, autosomal dominant cerebellar ataxia type II, autosomal dominant cerebellar ataxia type II caused by mutation in ATXN7
26 clinical trials for this condition and its sub-types, 7 tagged with Spinocerebellar ataxia 7 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug could slow rare brain disease that steals balance
Disease control OngoingThis phase 3 trial tests whether the drug troriluzole can slow the progression of spinocerebellar ataxia, a rare genetic disorder that affects coordination and balance. About 300 adults with different types of SCA are randomly assigned to take either troriluzole or a placebo dail…
Phase 3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a drug slow rare brain disease? new study uses Real-World data to find out
Disease control OngoingThis study looks at whether the drug troriluzole can slow the progression of spinocerebellar ataxia (SCA), a rare genetic disease that affects movement and balance. Researchers will compare 909 patients who took troriluzole for up to three years with similar patients who did not …
Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New study tracks rare disease SCA7 to uncover clues for future treatments
Knowledge-focused OngoingThis study follows 25 people with spinocerebellar ataxia type 7 (SCA7) for up to 5 years to learn how the disease changes vision, coordination, and thinking. Participants will have yearly eye exams, brain scans, and neurological tests. No treatment is given; the goal is to gather…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC